Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07776054

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07776054
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07776054. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2027-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Condition
DC Cardioversion
Intervention (Drug)
SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct07776054
Content hash
f0951d568e8843cb077c28473e8313c3ba8cb8c417b2f6d14d97a8167a595c4b